Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor

Imatinib, an orally administered protein-tyrosine kinase inhibitor (TKI) is indicated for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). Severe hepatotoxicity associated with imatinib is rare, and relationship to polymorphism of uridine diphosphate glucuro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ann Gastroenterol
Hauptverfasser: Saif, Muhammad Wasif, Smith, Melissa Hennessey, Maloney, Antonia, Diasio, Robert B.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Hellenic Society of Gastroenterology 2016
Schlagworte:
Case Report
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5049570/
https://ncbi.nlm.nih.gov/pubmed/27708529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.20524/aog.2016.0053
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge